- Home
- SUNE vs KLTO Comparison
SUNE vs KLTO Comparison
Compare SUNE & KLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUNE
- KLTO
- Stock Information
- Founded
- SUNE 1969
- KLTO 2019
- Country
- SUNE United States
- KLTO United States
- Employees
- SUNE N/A
- KLTO N/A
- Industry
- SUNE
- KLTO
- Sector
- SUNE
- KLTO
- Exchange
- SUNE NYSE
- KLTO NYSE
- Market Cap
- SUNE 5.6M
- KLTO 5.9M
- IPO Year
- SUNE N/A
- KLTO N/A
- Fundamental
- Price
- SUNE $1.55
- KLTO $0.92
- Analyst Decision
- SUNE
- KLTO
- Analyst Count
- SUNE 0
- KLTO 0
- Target Price
- SUNE N/A
- KLTO N/A
- AVG Volume (30 Days)
- SUNE 121.6K
- KLTO 5.9M
- Earning Date
- SUNE 08-12-2025
- KLTO 08-15-2025
- Dividend Yield
- SUNE N/A
- KLTO N/A
- EPS Growth
- SUNE N/A
- KLTO N/A
- EPS
- SUNE N/A
- KLTO N/A
- Revenue
- SUNE $56,279,194.00
- KLTO N/A
- Revenue This Year
- SUNE N/A
- KLTO N/A
- Revenue Next Year
- SUNE N/A
- KLTO N/A
- P/E Ratio
- SUNE N/A
- KLTO N/A
- Revenue Growth
- SUNE N/A
- KLTO N/A
- 52 Week Low
- SUNE $1.38
- KLTO $0.11
- 52 Week High
- SUNE $12,700.00
- KLTO $3.91
- Technical
- Relative Strength Index (RSI)
- SUNE N/A
- KLTO N/A
- Support Level
- SUNE N/A
- KLTO N/A
- Resistance Level
- SUNE N/A
- KLTO N/A
- Average True Range (ATR)
- SUNE 0.00
- KLTO 0.00
- MACD
- SUNE 0.00
- KLTO 0.00
- Stochastic Oscillator
- SUNE 0.00
- KLTO 0.00
About SUNE SUNATION ENERGY INC
SUNation Energy Inc provides households with sustainable solar energy, back-up power and security, control and predictability, and cost savings. The company provides a full range of installation services, including design, engineering, procurement, permitting, construction, grid connection, warranty, monitoring, and maintenance of residential solar energy systems. It also offers battery storage to customers in select markets and serves a limited number of enterprise customers.
About KLTO KLOTHO NEUROSCIENCES INC
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.